 |
110 Diseases |  |
158 Trials |
|
158 Trials |  |
1691 News |  |
| «12345678910111213...2728» |
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Enrollment closed, Enrollment change: Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer (clinicaltrials.gov) - Sep 13, 2023
P2, N=11, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=30 --> 11
- || Nubeqa (darolutamide) / Bayer, Orion Corp
Trial primary completion date: EORTC-1532: ODM-201 vs Androgen Deprivation Therapy in Hormone na (clinicaltrials.gov) - Sep 7, 2023
P2, N=61, Active, not recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Active, not recruiting | N=30 --> 11 Trial primary completion date: Dec 2022 --> Dec 2023
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion date, Metastases: Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic (clinicaltrials.gov) - Sep 7, 2023
P3, N=608, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Oct 2028 --> Jun 2024
- | Enrollment open: OFSET: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (clinicaltrials.gov) - Sep 5, 2023
P3, N=3960, Recruiting, Sponsor: NRG Oncology
Trial completion date: Oct 2028 --> Jun 2024 Not yet recruiting --> Recruiting
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, Rubraca (rucaparib) / Pharma& Schweiz
Trial suspension, Metastases: CASPAR: A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (clinicaltrials.gov) - Aug 31, 2023
P3, N=1002, Suspended, Sponsor: Alliance for Clinical Trials in Oncology
Not yet recruiting --> Recruiting Recruiting --> Suspended
- | cisplatin / Generic mfg., paclitaxel / Generic mfg.
Trial completion date, Metastases: SHPD002: Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Aug 29, 2023
P2/3, N=250, Active, not recruiting, Sponsor: RenJi Hospital
Recruiting --> Suspended Trial completion date: Oct 2022 --> Jan 2029
- | goserelin acetate / Generic mfg.
Observational data, Journal: Lipid Profile after Pharmacologic Discontinuation and Restoration of Menstruation in Women with Endometriosis: A 12-Month Observational Prospective Study. (Pubmed Central) - Aug 26, 2023
We aimed to evaluate the effects of goserelin-induced MC and subsequent menstrual restoration (MR) on lipid metabolism...In conclusion, GnRH-analog-induced MC alters lipid profiles at various levels, from standard blood lipid and lipoprotein profiles to several lipid species as detected by lipidomics analysis. Changes largely persist for at least 6 m after MR.
- | goserelin acetate / Generic mfg., exemestane / Generic mfg.
New P2/3 trial: Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients (clinicaltrials.gov) - Aug 24, 2023
P2/3, N=119, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | Viadur (leuprorelin implant) / J&J, Bayer, Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati
Trial completion date, Metastases: Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - Aug 22, 2023
P2, N=29, Active, not recruiting, Sponsor: City of Hope Medical Center
Changes largely persist for at least 6 m after MR. Trial completion date: Jun 2023 --> Dec 2023
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial initiation date: ARCH: Contributions to Hypertension With Androgen Deprivation Therapy (clinicaltrials.gov) - Aug 18, 2023
P4, N=228, Not yet recruiting, Sponsor: University of Colorado, Denver
Trial completion date: Jun 2023 --> Dec 2023 Initiation date: Jul 2023 --> Oct 2023
- ||| Nubeqa (darolutamide) / Bayer, Orion Corp, Verzenio (abemaciclib) / Eli Lilly
Enrollment open, Trial initiation date: Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer (clinicaltrials.gov) - Aug 14, 2023
P1/2, N=93, Recruiting, Sponsor: Praful Ravi, MB BCHir, MRCP
Initiation date: Jul 2023 --> Oct 2023 Not yet recruiting --> Recruiting | Initiation date: May 2023 --> Aug 2023
- | Epidaza (chidamide) / Chipscreen, Meiji Seika, Eisai, HUYA Bioscience
New P2 trial, Metastases: Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer (clinicaltrials.gov) - Aug 9, 2023
P2, N=102, Recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- (NOT SO) DIABETIC KETOACIDOSIS (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2043;
- | Ibrance (palbociclib) / Pfizer, Avastin (bevacizumab) / Roche, Halaven (eribulin mesylate) / Eisai
Journal, BRCA Biomarker, PD(L)-1 Biomarker, IO biomarker: A Case of Breast Carcinoma That Changed Subtype to Squamous Cell Carcinoma after Chemotherapy (Pubmed Central) - Jul 31, 2023
left breast cancer T2N2bM1(HEP)(ER 90%, PR 70%, HER2 2+, FISH-)at another hospital and participated in the PATHWAY study(tamoxifen plus goserelin plus palbociclib/placebo)...She was treated at our hospital thereafter, with capecitabine plus cyclophosphamide, palbociclib plus fulvestrant plus leuprorelin, paclitaxel plus bevacizumab, eribulin, EC therapy, and docetaxel...Therefore, left mastectomy plus pectoralis major muscle resection was performed. The patient died one month after the operation.
- || Opdivo (nivolumab) / Ono Pharma, BMS
Trial primary completion date, Combination therapy, Metastases: Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors (clinicaltrials.gov) - Jul 28, 2023
P2, N=60, Recruiting, Sponsor: Xiao X. Wei, MD
The patient died one month after the operation. Trial primary completion date: Jun 2023 --> Jun 2024
- | goserelin acetate / Generic mfg.
Trial completion: SHIP0804: Luteinizing Hormone-Releasing Hormone Agonist Therapy and Iodine I 125 Implant in Treating Patients With Previously Untreated Prostate Cancer (clinicaltrials.gov) - Jul 27, 2023
P3, N=421, Completed, Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Trial primary completion date: Jun 2023 --> Jun 2024 Active, not recruiting --> Completed
- goserelin acetate / Generic mfg., bicalutamide / Generic mfg.
Retrospective analysis of adjuvant systemic anti-hormonal therapy for resected androgen receptor-positive (AR+) salivary duct carcinoma (SDC) () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2450;
The adjuvant-treated patients generally exhibited better DFS and OS at 3 years than the control group (adjuvant: 46% and 68%, respectively, control: 33% and 54%, respectively). Conclusions Poor-risk AR+ SDC patients treated with adjuvant systemic anti-hormonal therapy showed prolonged, however not significant, DFS and OS as compared to non-adjuvant treated historical controls.
- Kisqali (ribociclib) / Novartis
First-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2? advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2010;
P2
These findings support RIB + ET over combo CT in pts with aggressive ABC even in the presence of visceral crisis. Table: 402P
- Kisqali (ribociclib) / Novartis
Invasive disease (Bilbao Auditorium - NCC) - Jul 27, 2023 - Abstract #ESMO2023ESMO_1283;
P3
EBC. Table: LBA23 Tx, n 3-y iDFS rate, % HR (95% CI) Menopausal status Premenopausal women & men Postmenopausal women RIB + NSAI, 1126 NSAI alone, 1132 RIB + NSAI, 1423 NSAI alone, 1420 91 89 90 86 0.72 (0.53-0.98) 0.78 (0.61-1.00) Anatomical stage II III RIB + NSAI, 1011 NSAI alone, 1034 RIB + NSAI, 1528 NSAI alone, 1512 94 91 87 84 0.76 (0.53-1.10) 0.74 (0.59-0.93) Nodal status N0 N1-N3 RIB + NSAI, 285 NSAI alone, 328 RIB + NSAI, 2261 NSAI alone, 2219 94 89 90 87 0.63 (0.34-1.17) 0.77 (0.63-0.94) Age 20% RIB + NSAI, 1199 NSAI alone, 1236 RIB + NSAI, 920 NSAI alone, 938 92 90 89 84 0.80 (0.59-1.08) 0.75 (0.56-1.00)
- | docetaxel / Generic mfg.
Trial completion date, Metastases: Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer (clinicaltrials.gov) - Jul 20, 2023
P1, N=20, Active, not recruiting, Sponsor: Medical University of South Carolina
Table: LBA23 Tx, n 3-y iDFS rate, % HR (95% CI) Menopausal status Premenopausal women & men Postmenopausal women RIB + NSAI, 1126 NSAI alone, 1132 RIB + NSAI, 1423 NSAI alone, 1420 91 89 90 86 0.72 (0.53-0.98) 0.78 (0.61-1.00) Anatomical stage II III RIB + NSAI, 1011 NSAI alone, 1034 RIB + NSAI, 1528 NSAI alone, 1512 94 91 87 84 0.76 (0.53-1.10) 0.74 (0.59-0.93) Nodal status N0 N1-N3 RIB + NSAI, 285 NSAI alone, 328 RIB + NSAI, 2261 NSAI alone, 2219 94 89 90 87 0.63 (0.34-1.17) 0.77 (0.63-0.94) Age 20% RIB + NSAI, 1199 NSAI alone, 1236 RIB + NSAI, 920 NSAI alone, 938 92 90 89 84 0.80 (0.59-1.08) 0.75 (0.56-1.00) Trial completion date: Jun 2023 --> Sep 2023
- | everolimus / Generic mfg.
New P2 trial, Metastases: BCTOP-L-M01: Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer (clinicaltrials.gov) - Jul 20, 2023
P2, N=265, Not yet recruiting, Sponsor: Fudan University
- | goserelin acetate / Generic mfg., megestrol / Generic mfg., triptorelin / Generic mfg.
New trial: Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer (clinicaltrials.gov) - Jul 14, 2023
P=N/A, N=57, Recruiting, Sponsor: Peking University People's Hospital
- || Firmagon (degarelix) / Astellas, Ferring
Clinical data, Observational data, Retrospective data, Journal: A multicenter, retrospective observational study investigating baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer treated with primary androgen deprivation therapy. (Pubmed Central) - Jul 6, 2023
This study clarified patient characteristics and long-term effectiveness of primary androgen deprivation therapy in real-world clinical practice. Japanese urologists appear to select appropriate primary androgen deprivation therapy based on patient background and tumour characteristics, with degarelix largely reserved for higher risk patients.
- || Erleada (apalutamide) / J&J
Trial completion, Trial completion date, Combination therapy, Metastases: YATAGARASU: A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (clinicaltrials.gov) - Jul 5, 2023
P2, N=31, Completed, Sponsor: Janssen Pharmaceutical K.K.
Japanese urologists appear to select appropriate primary androgen deprivation therapy based on patient background and tumour characteristics, with degarelix largely reserved for higher risk patients. Active, not recruiting --> Completed | Trial completion date: May 2024 --> May 2023
- || Kisqali (ribociclib) / Novartis
Trial completion date, Combination therapy, Metastases: AMALEE: Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (clinicaltrials.gov) - Jul 3, 2023
P2, N=376, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial completion date: May 2024 --> May 2023 Trial completion date: Dec 2025 --> Jul 2024
- | letrozole / Generic mfg.
Journal: Low-dose letrozole - an effective option for women with symptomatic adenomyosis awaiting IVF: a pilot randomized controlled trial. (Pubmed Central) - Jul 3, 2023
Trial completion date: Dec 2025 --> Jul 2024 Low-dose letrozole treatment is a low-cost alternative to a GnRH agonist, with comparable effects in improving the symptoms and sonographic features of adenomyosis in women awaiting IVF.
- | goserelin acetate / Generic mfg.
Trial completion date: SHIP0804: Luteinizing Hormone-Releasing Hormone Agonist Therapy and Iodine I 125 Implant in Treating Patients With Previously Untreated Prostate Cancer (clinicaltrials.gov) - Jun 26, 2023
P3, N=421, Active, not recruiting, Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Low-dose letrozole treatment is a low-cost alternative to a GnRH agonist, with comparable effects in improving the symptoms and sonographic features of adenomyosis in women awaiting IVF. Trial completion date: Mar 2023 --> Jun 2023
- | goserelin acetate / Generic mfg.
Journal: Androgen dihydrotestosterone promotes bladder cancer cell proliferation and invasion via EPPK1-mediated MAPK/JUP signalling. (Pubmed Central) - Jun 21, 2023
The growth of bladder tumours in BBN-treated mice was inhibited by the addition of the hormone inhibitor goserelin. Our findings indicated the potential oncogenic role and mechanism of DHT in BLCA pathogenesis through a non-AR pathway, which may serve as a novel therapeutic target for BLCA.
- |||| Erleada (apalutamide) / J&J
Trial primary completion date: PRIMORDIUM: A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (clinicaltrials.gov) - Jun 18, 2023
P3, N=412, Recruiting, Sponsor: Janssen Pharmaceutica N.V., Belgium
Our findings indicated the potential oncogenic role and mechanism of DHT in BLCA pathogenesis through a non-AR pathway, which may serve as a novel therapeutic target for BLCA. Trial primary completion date: Jan 2028 --> Jan 2030
- || goserelin acetate / Generic mfg.
Estoy esperando que a #IAPOS se le cante enviarme el inyectable mensual de goserelina (Zoladex) Cc @AstraZeneca @FundacionAZ ¿Hay faltante? ¿Se olvidaron? (Twitter) - Jun 13, 2023
- | AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New P3 trial: Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) (clinicaltrials.gov) - Jun 6, 2023
P3, N=766, Not yet recruiting, Sponsor: Fudan University
- ||| Kisqali (ribociclib) / Novartis
P3 data, Journal: Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib?+?endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. (Pubmed Central) - Jun 5, 2023
P3
NATALEE includes the broadest population of patients with HR+/HER2- EBC of any Phase III trial currently evaluating adjuvant CDK4/6 inhibitor treatment. ClinicalTrials.gov identifier: NCT03701334 (https://clinicaltrials.gov/ct2/show/NCT03701334).
- || goserelin acetate / Generic mfg., Herceptin (trastuzumab) / Roche
Çok iyi ne zaman hastanelerde kullanıma geçer herceptin zoladex devam ediyor. Nerden bilgi alabiliriz (Twitter) - Jun 5, 2023
- ||||||||| amcenestrant (SAR439859) / Sanofi
Trial termination, Metastases: AMEERA-5: Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer (clinicaltrials.gov) - Jun 2, 2023
P3, N=1068, Terminated, Sponsor: Sanofi
Active, not recruiting --> Terminated; The study was terminated based on the review by an independent data monitoring committee of the prespecified interim analysis of the Phase 3 AMEERA-5 efficacy data. No new safety signals were observed.
- || Biomarker, Trial completion date, Trial primary completion date: BOUQUET: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (clinicaltrials.gov) - Jun 2, 2023
P2, N=550, Recruiting, Sponsor: Hoffmann-La Roche
No new safety signals were observed. Trial completion date: Sep 2026 --> Dec 2028 | Trial primary completion date: Aug 2024 --> Dec 2026
- || Xtandi (enzalutamide capsule) / Pfizer, Astellas
Enrollment closed, Trial primary completion date, Surgery: STEEL: A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery (clinicaltrials.gov) - Jun 2, 2023
P2, N=188, Active, not recruiting, Sponsor: RTOG Foundation, Inc.
Trial completion date: Sep 2026 --> Dec 2028 | Trial primary completion date: Aug 2024 --> Dec 2026 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2024 --> Apr 2023
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial primary completion date, Metastases: Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) (clinicaltrials.gov) - Jun 1, 2023
P2, N=75, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2024 --> Apr 2023 Trial primary completion date: Jun 2023 --> Jun 2024
- | New P3 trial: OFSET: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (clinicaltrials.gov) - May 30, 2023
P3, N=3960, Not yet recruiting, Sponsor: NRG Oncology
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion date: Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - May 25, 2023
P2, N=19, Active, not recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Jun 2023 --> Jun 2024 Trial completion date: Apr 2023 --> Apr 2024
- || Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date: CARABELA: Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients (clinicaltrials.gov) - May 24, 2023
P2, N=200, Active, not recruiting, Sponsor: Spanish Breast Cancer Research Group
Trial completion date: Apr 2023 --> Apr 2024 Trial primary completion date: Feb 2023 --> Jun 2023
- || AAA603 / Novartis, Kisqali (ribociclib) / Novartis
New P1 trial, Combination therapy, Metastases: [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer (clinicaltrials.gov) - May 23, 2023
P1, N=45, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial primary completion date, HEOR, Real-world evidence, Real-world, Metastases: Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland (clinicaltrials.gov) - May 18, 2023
P=N/A, N=1, Recruiting, Sponsor: Pfizer
Trial primary completion date: Feb 2023 --> Jun 2023 Trial primary completion date: Apr 2023 --> Nov 2023
- ||| amcenestrant (SAR439859) / Sanofi
Trial completion date, Metastases: AMEERA-5: Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer (clinicaltrials.gov) - May 18, 2023
P3, N=1068, Active, not recruiting, Sponsor: Sanofi
Trial primary completion date: Apr 2023 --> Nov 2023 Trial completion date: Dec 2023 --> May 2023
- ||| Opdivo (nivolumab) / Ono Pharma, BMS
Enrollment open, Combination therapy, Metastases: Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors (clinicaltrials.gov) - May 17, 2023
P2, N=60, Recruiting, Sponsor: Xiao X. Wei, MD
Trial completion date: Dec 2023 --> May 2023 Suspended --> Recruiting
- ||||| Baituowei (goserelin acetate sustained-release microspheres for injection) / Luye Group, BeiGene
Trial completion: Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX (clinicaltrials.gov) - May 16, 2023
P3, N=188, Completed, Sponsor: Luye Pharma Group Ltd.
Suspended --> Recruiting Recruiting --> Completed
- | goserelin acetate / Generic mfg.
Trial completion date, Real-world evidence, Real-world: Zoladex (clinicaltrials.gov) - May 15, 2023
P=N/A, N=1000, Recruiting, Sponsor: AstraZeneca
Recruiting --> Completed Trial completion date: Feb 2024 --> Nov 2023
- || goserelin acetate / Generic mfg.
Pues por casualidad, a mi me dejaron escoger entre quimioterapia y tratamiento hormonal (mi cáncer de mama estaba en los límites) y escogí tratamiento hormonal con Zoladex por 1 año... De eso hace ya más de 20 años o sea LA ELECCIÓN ES FACTIBLE. (Twitter) - May 13, 2023
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion, Metastases: LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - May 10, 2023
P2, N=71, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial completion date: Feb 2024 --> Nov 2023 Active, not recruiting --> Completed
- | Erleada (apalutamide) / J&J
Trial completion date, Combination therapy, Metastases: YATAGARASU: A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (clinicaltrials.gov) - Apr 28, 2023
P2, N=31, Active, not recruiting, Sponsor: Janssen Pharmaceutical K.K.
Active, not recruiting --> Completed Trial completion date: May 2023 --> May 2024
- Cardiovascular comorbidities and cardiovascular events in patients with metastatic prostate cancer. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6039;
Addition of abiraterone to ADT increase the risk of cardiovascular events. Physicians should monitor their patients in order to early detect any abnormality, and should encourage them to adopt a healthier lifestyle.